Oragenics has announced a new license agreement with Inspirevax (formerly Biodextris) for use of Inspirevax's BDX301 intranasal mucosal adjuvant in Oragenic's NT-CoV2-1 intranasal COVID-19 vaccine candidate. The company said that the deal includes payments for the achievement of clinical, regulatory and commercial milestones, as well as tiered royalty payments. In … [Read more...] about Oragenics licenses intranasal mucosal adjuvant from Inspirevax for development of NT-CoV2-1 intranasal vaccine
Business
Vistagen gets US patent for PH80 pherine nasal spray for the treatment of migraine
According to Vistagen, the US Patent and Trademark Office (USPTO) has granted US Patent 11,419,881 covering the company's PH80 pherine nasal spray for treatment of migraine until 2040. The company says that "PH80 is an investigational pherine nasal spray designed with a potential rapid-onset mechanism of action that is fundamentally differentiated from all currently … [Read more...] about Vistagen gets US patent for PH80 pherine nasal spray for the treatment of migraine
Aerami expands development of AER-901 inhaled imatinib to include PH-ILD
Aerami Therapeutics announced that it will develop its AER-901 nebulized imatinib for pulmonary hypertension associated with interstitial lung disease (PH-ILD) in addition to pulmonary arterial hypertension (PAH). The FDA granted orphan drug designation to AER-901 for the PAH indication in August 2021, and the company says that it recently completed a Phase 1 trial of … [Read more...] about Aerami expands development of AER-901 inhaled imatinib to include PH-ILD
ARS Pharmaceuticals reacquires European rights to ARS-1 intranasal epinephrine from Recordati
According to ARS Pharmaceuticals, Recordati has returned the European marketing rights to ARS-1 epinephrine nasal spray (Neffy) in return for an unspecified amount up front plus future milestone payments connected to European approval and launch and royalties on sales in the EU, UK and other countries covered by the original deal. In September 2020, Recordati … [Read more...] about ARS Pharmaceuticals reacquires European rights to ARS-1 intranasal epinephrine from Recordati
Impel announces “streamlining plan,” halts development of INP105 intranasal olanzapine
Impel Pharmaceuticals announced that it will cut 16% of its workforce and halt development of INP105 intranasal olanzapine for the treatment of agitation in autism spectrum disorder. The company also said that its Chief Medical Officer, Stephen Shrewsbury, will be leaving Impel at the end of March. According to the company, the move will allow the company to … [Read more...] about Impel announces “streamlining plan,” halts development of INP105 intranasal olanzapine
BiomX announces data from Phase 1b trial of its BX004 inhaled phage cocktail for the treatment of lung infections in CF patients
Israeli biotech BiomX has announced data from the first part of a Phase 1b/2a trial of the company's BX004 nebulized phage cocktail for the treatment of P. aeruginosa lung infections in cystic fibrosis patients demonstrating a reduction in P. aeruginosa burden. The first portion of the study, which is supported by the Cystic Fibrosis Foundation, enrolled 9 CF patients … [Read more...] about BiomX announces data from Phase 1b trial of its BX004 inhaled phage cocktail for the treatment of lung infections in CF patients
AAHI gets $3 million for development of antiviral nasal spray
The non-profit Access to Advanced Health Institute (formerly the Infectious Disease Research Institute) said that it has received an award of up to $3 million for development of a prototype antiviral nasal spray from the US Department of Defense (D0D). The news comes soon after AAHI announced that it had received an award of worth up to $9.9 million for development of … [Read more...] about AAHI gets $3 million for development of antiviral nasal spray
Codagenix raises $25 million for development of CodaVax-RSV intranasal vaccine against RSV
Codagenix said that it has completed a $25 million Series B extension financing, with funds primarily going to support development of its CodaVax-RSV intranasal live attenuated vaccine against respiratory syncytial virus. The FDA recently granted Fast Track designation to CodaVax-RSV. Investors in this funding round included the Serum Institute of India, Euclidean … [Read more...] about Codagenix raises $25 million for development of CodaVax-RSV intranasal vaccine against RSV
Alveolus Bio gets $2.5 million SBIR FastTrack grant for development of inhaled live biotherapeutic
Alveolus Bio has received a 3-year Small Business Innovation Research (SBIR) FastTrack grant worth approximately $2.5 million from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) for development of an inhaled biotherapeutic for the treatment of COPD, the company said. The company's AB1000 inhaled live biotherapeutic … [Read more...] about Alveolus Bio gets $2.5 million SBIR FastTrack grant for development of inhaled live biotherapeutic
Spexis gets funding for Phase 3 trials of ColiFin inhaled colistimethate sodium
Spexis has announced a deal with SPRIM Global Investments (SGI) for funding of up to half of Spexis' costs related to Phase 3 development of ColiFin nebulized colistimethate sodium for the treatment of P. aeruginosa lung infections in patients with cystic fibrosis. Spexis was formed in December 2021 through a merger of Polyphor, which was developing inhaled … [Read more...] about Spexis gets funding for Phase 3 trials of ColiFin inhaled colistimethate sodium